Tag: pembrolizumab

Japan’s MHLW grants priority review for PADCEV and KEYTRUDA combo in urothelial cancer

businessnewstoday- February 18, 2024

In a significant development in the fight against urothelial cancer, Astellas Pharma Inc. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has awarded ... Read More

Merck’s KEYTRUDA shows 38% reduction in death risk for renal cell carcinoma patients in Phase 3 KEYNOTE-564 trial

businessnewstoday- January 29, 2024

Merck & Co., Inc., a global healthcare leader, has recently unveiled groundbreaking results from its Phase 3 KEYNOTE-564 trial. This pivotal study demonstrates that KEYTRUDA, ... Read More

Advancing bladder cancer treatment: EMA scrutinizes Astellas-Pfizer’s innovative therapy

businessnewstoday- January 28, 2024

A groundbreaking development in bladder cancer treatment is on the horizon as Astellas Pharma Inc. and Pfizer Inc. await the European Medicines Agency’s (EMA) review ... Read More

Imugene’s VAXINIA trial shows promising early results for solid tumours

businessnewstoday- November 6, 2023

Imugene Limited (ASX: IMU), a prominent player in the immuno-oncology field, has released an encouraging update on its Phase 1 MAST trial, which evaluates the ... Read More

Gilead’s EVOKE-02 study of Trodelvy, KEYTRUDA combo shows promise in NSCLC

businessnewstoday- September 10, 2023

Gilead Sciences, Inc. announced early data showcasing promising clinical activity of Trodelvy in combination with Merck's KEYTRUDA for first-line treatment of metastatic non-small cell lung ... Read More

ENB Therapeutics completes Phase 1 trial enrollment for ENB-003

businessnewstoday- July 19, 2023

ENB Therapeutics, a biotechnology firm working on therapeutics targeting the endothelin B receptor (ETBR), announced the completion of its international Phase 1 ENBOLDEN-101 trial enrollment. ... Read More

Moderna, Merck get FDA breakthrough status for mRNA-4157/V940, KEYTRUDA combo in melanoma

businessnewstoday- February 23, 2023

Moderna and Merck announced that the investigational personalized mRNA cancer vaccine mRNA-4157/V940 in combination with the latter’s lung cancer drug KEYTRUDA (pembrolizumab) has been given ... Read More

Cue Biopharma gets FDA fast track status for CUE-101 in HPV16+ R/M HNSCC

businessnewstoday- October 5, 2022

Cue Biopharma has been granted fast track designation for CUE-101 from the US Food and Drug Administration (FDA) for the treatment of a type of ... Read More

PDS Biotechnology gets FDA fast track status for PDS0101

pallavi123- June 5, 2022

PDS Biotechnology has secured fast track designation to its PDS0101 in combination with Merck’s KEYTRUDA (pembrolizumab) from the US Food and Drug Administration (FDA) for ... Read More

Seattle Genetics signs $4.4bn worth oncology deals with Merck

pharmanewsdaily- September 14, 2020

US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major ... Read More